Literature DB >> 8708992

Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment.

S Wanwimolruk1, S M Wong, H Zhang, P F Coville, R J Walker.   

Abstract

Our previous studies have shown that cigarette smoking and rifampicin pretreatment enhance the elimination of quinine, metabolism assumed, by analogy with quinidine, to be carried out by CYP3A (P450IIIA). This finding is unexpected since it has been shown that smoking induces the CYP1A rather than the CYP3A enzyme family, suggesting that the metabolism of quinine may be catalysed by CYP1A. Therefore, we conducted this study to identify possible quinine metabolites in human urine and to determine which metabolic pathway is induced by cigarette smoking and rifampicin pretreatment. A specific HPLC procedure was employed to identify metabolites of quinine in urine samples collected from healthy volunteers after an oral dose of 600 mg quinine sulphate. The results showed that there were at least seven possible metabolites of quinine detected in human urine. Three of these were identified as 2'-oxoquininone, quinine glucuronide and 3-hydroxyquinine. The 3-hydroxyquinine appeared to be a major metabolite of quinine in urine samples from every subject who took an oral dose of quinine. Although cigarette smoking and rifampicin pretreatment were shown to cause a marked increase in the elimination of quinine there were no significant changes in the formation of 3-hydroxyquinine as measured in the urine samples. This suggests that the effects of smoking and rifampicin are more complicated than we expected and require further investigation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8708992     DOI: 10.1111/j.2042-7158.1995.tb03277.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.

Authors:  P A De Smet; J R Brouwers
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

4.  Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria.

Authors:  S Pukrittayakamee; S Prakongpan; S Wanwimolruk; R Clemens; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria.

Authors:  S Pukrittayakamee; S Wanwimolruk; K Stepniewska; A Jantra; S Huyakorn; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?

Authors:  Sompon Wanwimolruk; Mary F Paine; Susan N Pusek; Paul B Watkins
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

7.  CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever.

Authors:  Sean R Marcsisin; Xiannu Jin; Theresa Bettger; Nicholas McCulley; Jason C Sousa; G Dennis Shanks; Babu L Tekwani; Rajnish Sahu; Gregory A Reichard; Richard J Sciotti; Victor Melendez; Brandon S Pybus
Journal:  Malar J       Date:  2013-06-21       Impact factor: 2.979

8.  A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.

Authors:  X J Zhao; T Ishizaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.